Addressing the Unmet Needs in KRAS G12C–Mutated Solid Tumors | Supplements And Featured Publications

Adagrasib Elicits Responses in KRAS G12C–Mutant NSCLC

August 12, 2022

Joshua K. Sabari, MD, discusses the significance of adagrasib as an agent with favorable central nervous system penetration and importance of performing next-generation sequencing in all patients with non–small cell lung cancer to detect KRAS G12C mutations.

KRYSTAL-12 Investigators Seek to Confirm Adagrasib’s Role in KRAS G12C–Mutant NSCLC

July 01, 2022

Efforts to unlock treatment modalities targeting KRAS mutations have ebbed and flowed for patients with non–small cell lung as investigators face resistance, intolerable toxicity profiles, and a lack of available binding pockets to guide treatment development.